US009409947B2

(12) **United States Patent**
Myasoedov et al.

(10) **Patent No.: US 9,409,947 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **METHOD FOR PRODUCING A RECOMBINANT PEPTIDE AND RESULTANT PEPTIDE**

(71) Applicant: **"IVIX" Ltd.**, Moscow (RU)

(72) Inventors: **Nikolay Fedorovich Myasoedov**, Moscow (RU); **Lyudmila Alexandrovna Andreeva**, Moscow (RU); **Dmitriy Viktorovich Golikov**, Moscow (RU)

(73) Assignee: **"IVIX" LTD.**, Moscow (RU)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/388,080**

(22) PCT Filed: **May 28, 2013**

(86) PCT No.: **PCT/RU2013/000433**

§ 371 (c)(1),
(2) Date: **Sep. 25, 2014**

(87) PCT Pub. No.: **WO2013/151467**

PCT Pub. Date: **Oct. 10, 2013**

(65) **Prior Publication Data**

US 2015/0111837 A1 Apr. 23, 2015

(30) **Foreign Application Priority Data**

Mar. 28, 2012 (RU) 2012111965

(51) **Int. Cl.**

C07K 7/06	(2006.01)
A61K 38/08	(2006.01)
C07K 5/103	(2006.01)
C07K 5/08	(2006.01)
C07K 5/10	(2006.01)
A61K 38/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 7/06*** (2013.01); ***C07K 5/0802*** (2013.01); ***C07K 5/1002*** (2013.01); ***C07K 5/1013*** (2013.01); *A61K 38/00* (2013.01); *A61K 38/08* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,932,548	A	8/1999	Deghenghi
5,955,421	A	9/1999	Deghenghi
6,211,156	B1	4/2001	Argiolas et al.
2009/0111161	A1	4/2009	Jones et al.
2010/0095987	A1	4/2010	Jones et al.
2010/0190722	A1	7/2010	Bevec et al.
2010/0197572	A1	8/2010	Bevec et al.
2010/0204143	A1	8/2010	Bevec et al.
2010/0204148	A1	8/2010	Bevec et al.
2010/0210534	A1	8/2010	Bevec
2010/0210567	A1	8/2010	Bevec
2010/0273700	A1	10/2010	Bevec et al.
2010/0286028	A1	11/2010	Bevec et al.
2011/0081711	A1	4/2011	Jones et al.
2012/0129791	A1	5/2012	Myasoedov et al.

FOREIGN PATENT DOCUMENTS

CN	101302246		11/2008
EA	013948		8/2010
EA	200900804		8/2010
RU	1124544		1/1995
RU	2 058 791		4/1996
RU	2 155 065		8/2000
RU	2 264 823		1/2004
RU	2 252 779		5/2005
RU	2 290 195		12/2006
RU	2 404 793		11/2010
RU	2411249	C2 *	2/2011
WO	WO 94/22460		10/1994
WO	WO 01/34171		5/2001
WO	WO 2009/033678		3/2009
WO	WO 2009/058679		5/2009
WO	WO 2013151467	A2 *	10/2013 ..... C07K 7/06

OTHER PUBLICATIONS

Shevchenko et al., "Synthesis of Tritium-Labeled Selank", Radiochemistry, 2006, vol. 48, No. 3, pp. 296-300.*
UniProtKB/Swiss-Prot: Q8WTQ1.2; D104A_HUMAN; Jul. 2015; pp. 1-3.*
Semple et al., "Duplication and selection in the evolution of primate __-defensin genes", Genome Biology, 2003, pp. R31.1-R31.11.*
Patil et al., "Cross-species analysis of the mammalian __-defensin gene family: presence of syntenic gene clusters and preferential expression in the male reproductive tract", Comparative Genomics, 2005, pp. 5-17.*
GenScript Peptide Calculator, Peptide Sequence TKP, obtained from https://www.genscript.com on Aug. 21, 2015.*
UniProtKB/Swiss-Prot: Q8WTQ1.2, 2015, pp. 1-3.*
Semion et al., "Antinociceptive action of the SP14 tetrapeptide and of some tuftsin analogs", Pol. J. Pharmacol Pharm., 1990, pp. 393-401.*
Dagan et al., "Tuftsin Analogues: Synthesis, Structure-Function Relationships, and Implications for Specificity of Tuftsin's Bioactivity", Journal of Medicinal Chemisty, 1986, pp. 1961-1968.*
Andreeva et al., "The Perspectives of Development of New Peptide Preparations for Clinical Use Which Have Anti-Infective and Immune-Modulating Activity", Infekc. immun., 2011, pp. 171-176.*
Nair et al., "Interactions of Radiolabeled Tuftsin with Human Neutrophils", Immunochemistry, 1978, pp. 901-907.*
Chipens et al., "Elongated and Cyclic Analogues of Tuftsin and Rigin", Peptides, Proceedings of the Sixteeth European Peptide Symposium, 1981, pp. 445-450.*
Ashmarin et al., "A Comparative Analysis of the Distribution of Glyprolines after Their Administration by Different Ways", Russian Journal of Bioorganic Chemistry, 2008, pp. 415-420.*

(Continued)

Primary Examiner — Lianko Garyu

(74) *Attorney, Agent, or Firm* — Troutman Sanders LLP

(57) **ABSTRACT**

The invention relates to peptides with the following general formula:

A-Thr-Lys-Pro-B-C-D-X, where:

A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly
B—0, Gly, Asp, Trp, Gln, Asn, Tyr, Pro, Arg
C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys
D—0, Val, Gly, Tyr, Trp, Phe, His
X—OH, OCH_3, NH_2,

where 0 is no amino acid residue, provided that if A≠0, then B and/or C and/or D≠0, if B≠0, then C and/or D≠0, excluding the peptides Phe-Thr-Lys-Pro-Gly (SEQ ID NO: 1), Thr-Lys-Pro-Pro-Arg (SEQ ID NO: 2), Thr-Lys-Pro-Arg-Gly (SEQ ID NO: 3).

36 Claims, 3 Drawing Sheets